Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion

The transaction is structured arsenic a 100% banal deal, though Tempus has the enactment to wage up to 50% of the information successful cash, financed done currency connected manus and existing recognition facilities. The deal, approved by some boards, is expected to adjacent successful precocious 2026 oregon aboriginal 2027, pending Personalis shareholder support and regulatory clearances.

Both stocks fell aft the announcement. Tempus AI banal dropped and Personalis banal declined 13%, according to Barron's. The declines were attributed to the deal's stock-based structure, according to Reuters. Needham downgraded Personalis banal to Hold from Buy pursuing the announcement, according to Barron's.

The acquisition centers connected Personalis' NeXT Personal test, which uses minimal residual illness exertion to observe traces of circulating tumor DNA successful humor — allowing physicians to show whether crab remains oregon has returned aft treatment. The trial presently has Medicare sum successful 3 indications.

The acquisition builds connected a commercialized narration the 2 companies formed successful November 2023, erstwhile Tempus took an concern presumption successful Personalis and began bringing the NeXT Personal trial to market. Tempus already held an ownership involvement successful Personalis earlier the acquisition agreement.

"MRD is simply a ample and rapidly increasing marketplace with the imaginable to genuinely alteration however crab patients are monitored, helping clinicians marque faster and much informed decisions erstwhile crab recurs," Tempus CEO Eric Lefkofsky said successful a statement. "With objective adoption and reimbursement momentum building, we are collectively good positioned to seizure this opportunity."

Personalis CEO Chris Hall said successful a connection that the transaction gives the institution "the scale, complementary capabilities and resources to accelerate innovation and present adjacent greater worth to patients, clinicians and biopharma partners."

Tempus and Personalis qualify the MRD marketplace arsenic a $20 cardinal opportunity. Personalis reported preliminary second-quarter gross of $22.4 cardinal and delivered 10,384 objective tests successful the quarter, a 33% summation successful trial measurement from the anterior quarter.